

## Utilization of blood cultures versus T2 Candida Panel for Candida species detection in a large community hospital

Rachel Chappell<sup>1,2</sup>, Pharm.D. candidate; Lauren Tepool<sup>1,2</sup>, Pharm.D. candidate; Taylor Steuber<sup>1,2</sup>, Pharm.D., BCPS; Jonathan Edwards<sup>2</sup>, Pharm.D., BCPS-AQID, BCGP; Adam Sawyer<sup>2</sup>, Pharm.D., BCPS, BCCCP

<sup>1</sup>Auburn University Harrison School of Pharmacy – Huntsville, Alabama

<sup>2</sup>Huntsville Hospital Department of Pharmacy – Huntsville, Alabama

### Background

- Candidemia is associated with a mortality rate around 40% in hospitalized patients
- Blood cultures have been the traditional methods of diagnosing candidemia; however, they can take 2-5 days to result and have a poor sensitivity of approximately 50%
- The T2 Candida Panel is a rapid diagnostic test with higher sensitivity and specificity than traditional blood cultures with results in less than six hours
- At Huntsville Hospital we have been evaluating the T2 Candida Panel utilization for the past 4 years
- The continued utilization of blood cultures to detect fungal infections versus the T2 Candida Panel in patients with a suspected Candida bloodstream infection remains unclear.

### Purpose

To evaluate the utilization of the T2 Candida Panel (T2CP) versus blood cultures (BC) in detecting and treating candidemia at a large community hospital.

### Methods

- This study was a retrospective chart review that included patients with a BC positive for Candida species compared to patients with a positive T2CP from January 2012 to June 2018.
- Co-primary endpoints assessed included time to detection of candidemia and time to antifungal therapy.
- Additional endpoints included blood culture results, length of stay, and mortality.
- The student's t-test and chi-square test were used to analyze parametric and non-parametric data, respectively.
- A p-value of <0.05 was considered statistically significant.

### Results


- There was significantly higher percentage of Candida glabrata/krusei species identified in the T2CP group compared to the BC group.
- More patients in the T2CP group had an antifungal ordered at the time of the test.
- More patients in the BC positive group had concomitant bacteremia.
- The average time to detection of candidemia was significantly shorter in the T2CP group compared to BC group.
- The time to antifungal was also significantly shorter in the T2CP group compared to the BC group.
- The average length of stay was shorter in the BC positive group than the T2CP group.
- There was no difference in mortality between the two groups.

# The T2 Candida Panel led to faster detection and initiation of antifungal therapy compared to blood cultures.

Want a copy of the poster?  
Take a picture to activate the URL




## Results



### Select Characteristics of Population

| Variable                          | Blood Culture Positive (n=163) | T2 Positive (n=60) | p-value |
|-----------------------------------|--------------------------------|--------------------|---------|
| Age, years ± SD                   | 59.4 ± 15                      | 61.1 ± 17.4        | 0.474   |
| Male, n (%)                       | 93 (57.1)                      | 35 (58.3)          | 0.864   |
| Caucasian, n (%)                  | 123 (75.5)                     | 47 (78.3)          | 0.655   |
| Mortality, n (%)                  | 47 (28.9)                      | 15 (25)            | 0.571   |
| Broad Spectrum Antibiotics, n (%) | 131 (80.4)                     | 55 (91.7)          | 0.075   |
| Bacteremia, n (%)                 | 41 (25.2)                      | 4 (6.7)            | 0.002   |



## Discussion

- Of patients diagnosed with candidemia at our large community hospital, T2CP led to faster detection and initiation of antifungal compared to blood cultures.
- No difference was observed in mortality between groups, though length of stay was shorter in patients diagnosed by blood cultures.
- Utilizing the T2 Candida Panel may optimize treatment initiation for patients with candidemia, though the effect on clinical outcomes remains to be determined.

### References

- Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60: 892-899.
- Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of Candidiasis. Clinical Infect Dis 2016; 62: 1-50.

The authors have nothing to disclose.